The document summarizes 295 vaccines currently in development. It notes that vaccines have successfully prevented diseases like smallpox and measles. Today, biopharmaceutical companies are developing vaccines against malaria, meningococcal disease, and cancers like pancreatic and prostate. Developing new vaccines is challenging and requires thorough testing. Areas of focus include preventing infectious diseases and treating cancers. New scientific areas like genomics may help develop more vaccines to protect against life-threatening illnesses.

1. 2012 Report
Medicines in Development
Vaccines
presented by america’s biopharmaceutical
research companies
Nearly 300 Vaccines Are in Development;
Research Focuses on Prevention and Treatment
Vaccines in Development*
170
For many years, vaccines have been used Today, biopharmaceutical research companies
to successfully prevent diseases such as are developing 295 vaccines. Potential vac-
smallpox, measles, polio and other infectious cines in development include:
diseases. A 2007 study by the U.S. Centers for • recombinant vaccine against malaria.
A
102
Disease Control and Prevention (CDC) found
that cases of vaccine-preventable diseases • vaccine that protects infants against
A
had reached an all-time low in the United meningococcal disease, a leading cause
of meningitis.
States. The study found that hospitalizations
and deaths from nine infectious diseases had • genetically-modified vaccine designed
A
declined by more than 90 percent and nearly for the treatment of pancreatic cancer.
90 percent for another four diseases. Although many new promising vaccines are
being researched today, the vaccine devel-
These findings illustrate the major contribution
opment process is not an easy one. As with
that vaccines have made in saving countless
the development of all drugs, vaccines must
lives around the world. In the past several
survive many years of thorough testing before
years, many successful new vaccines have
they can be approved for use by the general
been developed, including one against human
12 public. Advances in other scientific fields,
8 papillomavirus (HPV) infections that can lead
7
such as genomics, are becoming increasingly
to cervical cancer, one to guard against pre-
useful in the development of new vaccines.
exposure to the anthrax virus, and a vaccine to
With the continued efforts of researchers, it is
gy
es
r
s
er
he
er
prevent pneumococcal infections in high-risk
nc
ler
as
rd
Ot
likely that we may have many more vaccines
Ca
ise
Al
so
populations.
Di
sD
to protect against life-threatening diseases in
gic
u
tio
olo
ec
But vaccines are not only for preventing infec- the near future.
ur
Inf
Ne
tious diseases. In 2010, a new cancer vaccine
* Some vaccines are listed in for the treatment of prostate cancer was
more than one category. approved in the United States, and many more
are in development.

2. Medicines in Development for Vaccines
Allergy
Product Name Sponsor Indication Development Status*
cat allergy vaccine Greer Laboratories perennnial allergic rhinitis due to Phase I
sublingual Lenoir, NC cat hair (800) 419-7302
food allergy epicutaneous DBV Technologies peanut hypersensitivity Phase I
immunotherapy Bagneux, France (Fast Track) www.dbv-technologies.com
grass pollen allergy ALK Abello seasonal allergic rhinitis Phase III
vaccine tablet Horsholm, Denmark (800) 672-6372
(immunotherapy) Merck
Whitehouse Station, NJ
grass pollen extract Stallergenes seasonal allergic rhinitis Phase III
sublingual vaccine Norwell, MA (781) 878-0018
house dust mite allergy Greer Laboratories allergic rhinitis Phase I
sublingual vaccine Lenoir, NC (800) 419-7302
house dust mite allergy ALK Abello allergic asthma Phase II
vaccine tablet Horsholm, Denmark (800) 672-6372
Merck
Whitehouse Station, NJ
peanut allergy vaccine Allertein Therapeutics peanut hypersensitivity Phase I
Fairfield, CT
Pollinex® Quattro Allergy Therapeutics prevention of grass pollen Phase III
injectable MPL allergy vaccine West Sussex, United Kingdom hypersensitivity, prevention of www.allergytherapeutics.com
ragweed hypersensitivity
-------------------------------------------------- -------------------------------------------
prevention of tree pollen Phase II
hypersensitivity www.allergytherapeutics.com
QGE031 Novartis Pharmaceuticals allergic diseases Phase I
(anti-IgE antibody) East Hanover, NJ (888) 669-6682
ragweed allergy immunotherapy Stallergenes seasonal allergic rhinitis Phase I
vaccine Norwell, MA (781) 878-0018
ragweed allergy vaccine Greer Laboratories seasonal allergic rhinitis Phase III
sublingual Lenoir, NC (800) 419-7302
ragweed allergy vaccine ALK Abello seasonal allergic rhinitis Phase III
sublingual tablet Horsholm, Denmark (800) 672-6372
Merck
Whitehouse Station, NJ
* For more information about a specific medicine in this report, please call the telephone number listed.
2 Medicines in Development Vaccines 2012

3. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
abagovomab Menarini ovarian cancer Phase III
(anti-idiotype mAb vaccine) Florence, Italy www.menarini.com
ADXS-HPV Advaxis recurrent cervical cancer, cervical Phase II
(live, attenuated Listeria Princeton, NJ intraepithelial neoplasia (609) 452-9813
monocytogenes [Lm]-based
vaccine)
AE37 Antigen Express breast cancer Phase II
(peptide vaccine) Worcester, MA (508) 852-8783
-------------------------------------------------- -------------------------------------------
ovarian cancer (combination Phase I
therapy), prostate cancer (508) 852-8783
AGS-003 Argos Therapeutics kidney cancer (combination therapy), Phase II
(personalized dendritic Durham, NC metastatic kidney cancer (919) 287-6300
cell-based immunotherapy) (monotherapy)
AlloStim™ Novo Energies hematological malignancies, Phase I/II
immunotherapeutic vaccine Montreal, Canada solid tumors (514) 840-3697
anti-GnRH vaccine Novartis Vaccines Diagnostics prostate cancer Phase I/II
Cambridge, MA (617) 871-7000
Pepscan Therapeutics
Lelystad, Netherlands
astuprotimut-R GlaxoSmithKline malignant melanoma, non-small-cell Phase III
(MAGE-A3 recombinant Rsch. Triangle Park, NC lung cancer (NSCLC) (888) 825-5249
antigen-specific cancer -------------------------------------------------- -------------------------------------------
immunotherapy) bladder cancer Phase II
(888) 825-5249
AVX-701 AlphaVax prevention of advanced or metastatic Phase I/II
Rsch. Triangle Park, NC CEA-expressing colorectal cancer (919) 595-0400
B7-2/GM-CSF NuVax Therapeutics cancer Phase I
cancer gene therapy vaccine Tustin, CA (714) 505-4461
BiovaxID® Biovest International indolent follicular lymphoma Phase III
B-cell lymphoma vaccine Tampa, FL (Fast Track) (813) 864-2558
(personalized lymphoma -------------------------------------------------- -------------------------------------------
vaccine) mantle-cell lymphoma Phase II
(813) 864-2558
BPX-101 Bellicum Pharmaceuticals prostate cancer Phase I/II
(dendritic cell vaccine) Houston, TX www.bellicum.com
breast cancer vaccine Quantum Immunologics breast cancer Phase I/II
(dendritic cell vaccine) Tampa, FL (813) 849-7885
Medicines in Development Vaccines 2012 3

4. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
cancer vaccine Immunovaccine ovarian cancer Phase I
Halifax, Canada (902) 492-1819
cancer vaccine Activartis Biotech glioblastoma (first-line therapy) Phase II
(autologous dendritic cell Vienna, Austria www.activartis.com
vaccine) -------------------------------------------------- -------------------------------------------
metastatic renal cancer in clinical trials
www.activartis.com
cancer vaccine Bayer HealthCare Pharmaceuticals follicular lymphoma (prevention of Phase I
(autologous idiotype vaccine) Wayne, NJ relapse) (888) 842-2937
cancer vaccine Cytokine PharmaSciences cancer Phase I
(fibrocyte vaccine) King of Prussia, PA (610) 687-1776
cancer vaccine MabVax Therapeutics sarcoma Phase II
(mAb vaccine) San Diego, CA (858) 259-9405
-------------------------------------------------- -------------------------------------------
breast cancer Phase I
(858) 259-9405
CB-10-01 Cosmo Pharmaceuticals malignant melanoma Phase II
Lainate, Italy www.cosmopharmaceuticals.
com
CDX-1401 Celldex Therapeutics solid tumors expressing the Phase I/II
Needham, MA NY-ESO-1 protein (781) 433-0771
CG201 CG Therapeutics solid tumors Phase II
Seattle, WA (206) 336-5604
CLL MaxCyte chronic lymphocytic leukemia (CLL) Phase I/II
immunotherapeutic Gaithersburg, MD (301) 944-1700
CRS-207 Aduro BioTech metastatic pancreatic cancer Phase II
Berkeley, CA (combination therapy) (510) 848-4400
CV-301 BN ImmunoTherapeutics metastatic breast cancer Phase II
(immunotherapeutic vaccine) (Bavarian Nordic) (650) 681-4660
Mountain View, CA
CVac™ Prima Biomed ovarian cancer Phase II/III
cancer vaccine Sydney, Australia www.primabiomed.com.au
MUC-1
4 Medicines in Development Vaccines 2012

5. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
DCVax®-Brain Northwest Biotherapeutics glioblastoma Phase II
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
(Orphan Drug)
DCVax®-Ovarian Northwest Biotherapeutics ovarian cancer, peritoneal cancer Phase I
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
DCVax®-Prostate Northwest BioTherapeutics prostate cancer Phase III
dendritic cell-based vaccine Bethesda, MD (240) 497-9024
dendritic cell cancer vaccine EMD Serono malignant melanoma Phase I
Rockland, MA (800) 283-8088
DN24-02 Dendreon HER2-positive urogenital cancer Phase II
(lapuleucel-T) Seattle, WA (adjuvant therapy) (877) 256-4545
(dendritic cell vaccine) -------------------------------------------------- -------------------------------------------
breast cancer, colorectal cancer, Phase I completed
ovarian cancer (877) 256-445
DPX-0907 Immunovaccine breast cancer, ovarian cancer, Phase I
Halifax, Canada prostate cancer (902) 492-1819
EC17 Endocyte kidney cancer Phase I
West Lafayette, IN (combination therapy) www.endocyte.com
ETBX-011 Etubics solid tumors Phase I
(adenovirus vector vaccine) Seattle, WA (206) 838-5110
FANG™ vaccine Gradalis malignant melanoma, ovarian cancer Phase II
(autologous tumor cell vaccine) Carrollton, TX (214) 442-8100
FBP vaccine Galena Biopharma endometrial cancer, ovarian cancer Phase I/II
(folate-binding protein Lake Oswego, OR (855) 855-4253
E39 vaccine) -------------------------------------------------- -------------------------------------------
breast cancer Phase I
(855) 855-4253
G-100 prophage cancer vaccine Agenus newly-diagnosed glioma Phase II
(Orphan Drug) Lexington, MA (781) 674-4400
G-200 prophage cancer vaccine Agenus recurrent glioma Phase II
(Orphan Drug) Lexington, MA (781) 674-4400
Medicines in Development Vaccines 2012 5

6. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
GI-4000 GlobeImmune colorectal cancer, pancreatic cancer Phase II
(therapeutic vaccine) Louisville, CO (303) 625-2700
-------------------------------------------------- -------------------------------------------
colorectal cancer (first-line therapy), Phase I
colorectal cancer (second-line (303) 625-2700
therapy), NSCLC
GI-6207 GlobeImmune metastatic cancer Phase I
(therapeutic vaccine) Louisville, CO (303) 625-2700
GI-6301 GlobeImmune solid tumors Phase I
(brachyury peptide vaccine) Louisville, CO (303) 625-2700
GRNVAC1 Geron acute myeloid leukemia (AML) Phase II
(telomerase-based cancer Menlo Park, CA (650) 473-7700
vaccine) -------------------------------------------------- -------------------------------------------
prostate cancer Phase I/II
(650) 473-7700
GSK2241658A GlaxoSmithKline metastatic melanoma Phase I
(NY-ESO-1 antigen-specific Rsch. Triangle Park, NC (888) 825-5249
cancer immunotherapeutic)
GV1001 KAEL-GemVax pancreatic cancer Phase I
(hTERT RNA vaccine) Seoul, South Korea www.kaelgemvax.com
(Orphan Drug)
GVAX® Breast BioSante Pharmaceuticals breast cancer Phase I
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Colorectal BioSante Pharmaceuticals colorectal cancer Phase I
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Leukemia BioSante Pharmaceuticals AML, chronic myeloid leukemia Phase II
immunotherapeutic vaccine Lincolnshire, IL (CML) (847) 478-0500
(Orphan Drug)
GVAX® Myeloma BioSante Pharmaceuticals multiple myeloma Phase II
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
GVAX® Pancreatic BioSante Pharmaceuticals pancreatic cancer Phase II
immunotherapeutic vaccine Lincolnshire, IL (847) 478-0500
(Orphan Drug)
GVAX® Prostate BioSante Pharmaceuticals prostate cancer Phase III
immunotherapeutic vaccine Lincolnshire, IL (Fast Track) (847) 478-0500
6 Medicines in Development Vaccines 2012

7. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
HS-110 Heat Biologics NSCLC (combination therapy) Phase II
Chapel Hill, NC (919) 240-7133
hTERT vaccine Merck cancer Phase I
(human telomerase reverse Whitehouse Station, NJ (800) 672-6372
transcriptase cancer vaccine) Vical (858) 646-1100
San Diego, CA
HyperAcute® Lung NewLink Genetics NSCLC Phase II
lung cancer immunotherapy Ames, IA (515) 296-5555
HyperAcute® Melanoma NewLink Genetics malignant melanoma Phase II
lung cancer immunotherapy Ames, IA (515) 296-5555
HyperAcute® Pancreas NewLink Genetics pancreatic cancer Phase III
algenpantucel-L Ames, IA (Fast Track) (515) 296-5555
(Orphan Drug)
ICT-107 ImmunoCellular Therapeutics glioblastoma Phase II
(autologous dendritic-cell Woodland Hills, CA (818) 992-2907
vaccine)
(Orphan Drug)
IDM-2101 Biotech Synergy NSCLC Phase II
(multi-epitope cancer vaccine) San Diego, CA (858) 459-6689
IMA901 immatics biotechnologies kidney cancer Phase III
(multiple tumor-associated Tuebingen, Germany www.immatics.com
peptides cancer vaccine)
IMCgp100 Immunocore malignant melanoma Phase 0
Oxon, United Kingdom www.immunocore.com
IMF-001 ImmunoFrontier solid tumors Phase I
(protein vaccine) Tokyo, Japan www.immunofrontier.com
IMT-1012 Immunotope breast cancer, ovarian cancer Phase I
(multi-peptide antigen Doylestown, PA (215) 253-4180
immunotherapeutics vaccine)
ISF35 Memgen CLL (monotherapy), Phase II
(recombinant immunotherapy) San Diego, CA non-Hodgkin’s lymphoma (858) 524-5400
-------------------------------------------------- -------------------------------------------
CLL (combination therapy) Phase I
(858) 524-5400
Medicines in Development Vaccines 2012 7

8. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
JVRS-100 Colby Pharmaceutical leukemia Phase I
(lipid-DNA complex vaccine) San Jose, CA (650) 333-3152
Lucanix® NovaRx NSCLC Phase III
belagenpumatucel-L San Diego, CA (Fast Track) (858) 552-8600
(cell-based therapeutic vaccine) -------------------------------------------------- -------------------------------------------
glioma Phase I
(858) 552-8600
LungVax® AVAX Technologies NSCLC Phase I/II
autologous cell vaccine Philadelphia, PA (215) 241-9760
M-200 prophage cancer vaccine Agenus metastatic melanoma Phase III
(Orphan Drug) Lexington, MA (Fast Track) (781) 674-4400
melanoma DNA vaccine Ichor Medical Systems malignant melanoma Phase I
San Diego, CA (858) 550-2022
Memorial Sloan-Kettering Cancer
Center
New York, NY
MVA-BN® Breast BN ImmunoTherapeutics breast cancer Phase I
HER-2/neu-based modified (Bavarian Nordic) (650) 681-4660
vaccinia ankara (MVA) vaccine Mountain View, CA
MVA-BN®-PRO BN ImmunoTherapeutics prostate cancer Phase I/II
(Bavarian Nordic) (650) 681-4660
Mountain View, CA
MVax® AVAX Technologies malignant melanoma Phase III
autologous cell vaccine Philadelphia, PA (215) 241-9760
NeuVax™ Galena Biopharma early-stage breast cancer Phase III
E75 cancer vaccine Lake Oswego, OR (prevention of relapse) (855) 855-4253
-------------------------------------------------- -------------------------------------------
prostate cancer Phase I/II
(855) 855-4253
Oncophage® Agenus renal cell carcinoma Phase II
vitespen Lexington, MA (Fast Track) (781) 674-4400
(Orphan Drug)
OncoVAX® Vaccinogen stage III colorectal cancer Phase II
colorectal cancer vaccine Frederick, MD (combination therapy) (301) 668-8400
-------------------------------------------------- -------------------------------------------
colorectal cancer Phase I/II
(Fast Track) (301) 668-8400
ONT-10 Oncothyreon solid tumors Phase I
Seattle, WA (206) 801-2100
8 Medicines in Development Vaccines 2012

9. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
OPT-822 Optimer Pharmaceuticals breast cancer Phase II
San Diego, CA (858) 909-0736
oral peptide cancer vaccine Immunitor cancer Phase I/II
Vancouver, Canada
oregovomab Quest PharmaTech ovarian cancer Phase I/II
(Orphan Drug) Edmonton, Canada (780) 448-1400
OVax® AVAX Technologies ovarian cancer Phase I/II
autologous tumor cell vaccine Philadelphia, PA (215) 241-9760
(Orphan Drug)
POL-103A Polynoma malignant melanoma Phase II
(polyvalent shed-antigen San Diego, CA (858) 205-2501
vaccine)
(Orphan Drug)
polyclonal antibody stimulator Cancer Advances gastric cancer, pancreatic cancer Phase III
(Orphan Drug) Durham. NC (see also other) (919) 361-2162
-------------------------------------------------- -------------------------------------------
colorectal cancer Phase II
(919) 361-2162
PRAME GlaxoSmithKline metastatic melanoma, NSCLC Phase I
antigen-specific cancer Rsch. Triangle Park, NC (888) 825-5249
immunotherapeutic
Prostvac™ BN ImmunoTherapeutics metastatic prostate cancer Phase III
prostate cancer vaccine (Bavarian Nordic) (Fast Track) (650) 681-4660
Mountain View, CA
Provenge® Dendreon recurrent early-stage prostate cancer Phase III
sipuleucel-T Seattle, WA (877) 256-4545
-------------------------------------------------- -------------------------------------------
early-stage prostate cancer Phase II
(neoadjuvant therapy) (877) 256-4545
PSMA VRP therapeutic vaccine Progenics Pharmaceuticals prostate cancer Phase I
Tarrytown, NY (914) 789-2800
PT107 Pique Therapeutics NSCLC Phase II
(allogeneic tumor cell vaccine) Durham, NC (919) 806-4395
recombinant soluble PSMA Progenics Pharmaceuticals prostate cancer Phase I
protein vaccine Tarrytown, NY (914) 789-2800
Medicines in Development Vaccines 2012 9

10. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
REIC gene therapy Momotaro-Gene prostate cancer Phase I
Okayama, Japan www.mt-gene.com
Reximmune-C® Epeius Biotechnologies breast cancer Phase I/II
personalized cancer vaccine San Marino, CA (626) 441-6695
rindopepimut Celldex Therapeutics glioblastoma (first-line therapy) Phase III
(Orphan Drug) Needham, MA (Fast Track) (781) 433-0771
-------------------------------------------------- -------------------------------------------
glioblastoma (combination therapy, Phase II
second-line therapy) (781) 433-0771
(Fast Track)
SL-701 Stemline Therapeutics glioma Phase I/II
(dendritic cell vaccine) New York, NY (212) 831-1111
Stimuvax® EMD Serono NSCLC (Fast Track) Phase III
emepepimut-S Rockland, MA (800) 283-8088
Oncothyreon -------------------------------------------------- (206) 769-9219
Seattle, WA prostate cancer -------------------------------------------
Phase II
(800) 283-8088
(206) 769-9219
TAG vaccine Gradalis solid tumors Phase I
Carrollton, TX (214) 442-8100
TeloB-Vax Adamis Pharmaceuticals prostate cancer Phase I
telomerase cancer vaccine San Diego, CA www.adamispharma.com
tipapkinogene sovacivec Transgene cervical intraepithelial neoplasia Phase II
Rockville, MD (301) 816-5421
TroVax® Oxford BioMedica hormone refractory prostate cancer Phase II
tumor-associated antigen Oxford, United Kingdom www.oxfordbiomedica.co.uk
vaccine
TVI-Brain-1 TVAX Biomedical glioma Phase II
(cellular immunotherapy Lenexa, KS (913) 492-2221
vaccine)
TVI-Kidney-1 TVAX Biomedical renal cell carcinoma in clinical trials
(cellular immunotherapy Lenexa, KS (913) 492-2221
vaccine)
V503 Merck prevention of cervical cancer, Phase III
(virus-like particle [VLP] Whitehouse Station, NJ prevention of vulvovaginal cancer (800) 672-6372
vaccine) (see also infectious diseases)
10 Medicines in Development Vaccines 2012

11. Medicines in Development for Vaccines
Cancer
Product Name Sponsor Indication Development Status
V505 Merck prevention of cervical cancer Phase II completed
Whitehouse Station, NJ (see also infectious diseases) (800) 672-6372
V930/V932 Merck cancer Phase I
(plasmid DNA cancer vaccine) Whitehouse Station, NJ (800) 672-6372
Vical (858) 646-1100
San Diego, CA
V935 Geron solid tumors Phase I
(telomerase inhibitor vaccine) Menlo Park, CA (650) 473-7700
Merck (800) 672-6372
Whitehouse Station, NJ
verpasep caltespen Akela Pharma cervical intraepithelial neoplasia Phase I completed
Austin, TX (512) 834-0449
VGX-3100 Inovio Pharmaceuticals cervical intraepithelial neoplasia Phase II
Blue Bell, PA (see also infectious diseases) (877) 446-6846
WT1 antigen specific cancer GlaxoSmithKline AML Phase II
immunotherapeutic Rsch. Triangle Park, NC (888) 825-5249
-------------------------------------------------- -------------------------------------------
breast cancer Phase I
(888) 825-5249
Infectious Diseases
Product Name Sponsor Indication Development Status
ACAM-Cdiff sanofi pasteur Clostridium difficile infections Phase II
(toxoid vaccine) Swiftwater, PA (800) 822-2463
ACE527 ACE Biosciences prevention of traveler’s diarrhea Phase II
(oral pentavalent vaccine) Odense, Denmark caused by Escherichia coli infections www.acebiosciences.com
TD Vaccines www.tdvaccines.com
Skorping, Denmark
Ad26.ENVA.01 Crucell prevention of HIV infection Phase I
HIV-1 recombinant vaccine Leiden, Netherlands www.crucell.com
ADVAX Aaron Diamond AIDS Research HIV infection prevention Phase I completed
(DNA vaccine) Center (212) 448-5000
New York, NY (212) 847-1111
International AIDS Vaccine Initiative -------------------------------------------------- -------------------------------------------
New York, NY HIV infection prevention Phase I completed
Ichor Medical Systems (new delivery system) (212) 448-5000
San Diego, CA (212) 847-1111
Medicines in Development Vaccines 2012 11

12. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Aflunov™ Novartis Vaccines Diagnostics prevention of influenza A virus H5N1 Phase II
influenza A virus H5N1 vaccine Cambridge, MA subtype (pre-pandemic) (617) 871-7000
AG-707 Agenus treatment of herpes simplex virus Phase I completed
(herpes simplex vaccine) Lexington, MA infections (781) 674-4400
AGS-004 Argos Therapeutics HIV-1 infection Phase II
(personalized dendritic Durham, NC (919) 287-6300
cell-based immunotherapy)
anthrax transdermal vaccine Intercell USA anthrax Phase I
Gaithersburg, MD (301) 556-4500
ANZ-521 Aduro BioTech treatment of hepatitis C Phase I
(recombinant vaccine) Berkeley, CA (510) 848-4400
AV-7909 Emergent BioSolutions anthrax Phase I
(anthrax vaccine adsorbed with Rockville, MD (301) 795-1800
adjuvant)
AVX-101 AlphaVax prevention of HIV-1 infection Phase I completed
(monovalent HIV vaccine) Rsch. Triangle Park, NC (919) 595-0400
AVX-502 AlphaVax prevention of influenza virus Phase I/II
Rsch. Triangle Park, NC infections in the elderly (919) 595-0400
BioThrax® Emergent BioSolutions anthrax (post-exposure prevention) Phase III
anthrax vaccine adsorbed Rockville, MD (Fast Track) (301) 795-1800
botulinum toxin recombinant DynPort Vaccine Company botulism Phase II
vaccine Frederick, MD (301) 607-5000
chikungunya virus vaccine Inviragen chikungunya virus infections Phase II
Fort Collins, CO (970) 672-4918
CholeraGarde® Vaccine Technologies cholera Phase II
cholera vaccine live attenuated Boston, MA (617) 358-5011
ChronVac-C® Inovio Pharmaceuticals treatment of hepatitis C Phase II
hepatitis C DNA vaccine Blue Bell, PA (877) 446-6846
ChronTech Pharma
Huddinge, Sweden
cytomegalovirus vaccine AlphaVax prevention of cytomegalovirus Phase I
(AVX-601) Rsch. Triangle Park, NC infections (617) 871-7000
Novartis Vaccines Diagnostics
Cambridge, MA
12 Medicines in Development Vaccines 2012

13. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
DCVax-001 Celldex Therapeutics prevention and treatment of HIV Phase I
(recombinant protein vaccine) Needham, MA infection (781) 433-0771
dengue DNA vaccine U.S. Naval Medical Research Center prevention of dengue fever Phase I
Silver Spring, MD (858) 646-1100
Vical
San Diego, CA
dengue fever vaccine GlaxoSmithKline prevention of dengue fever Phase II completed
Rsch. Triangle Park, NC (888) 825-5249
dengue fever vaccine sanofi pasteur prevention of mild to severe dengue Phase III
Swiftwater, PA fever (800) 822-2463
(Fast Track)
DENVax™ Inviragen dengue Phase I
tetravalent hybrid dengue virus Fort Collins, CO (970) 672-4918
vaccine
DermaVir™ Patch Genetic Immunity treatment of HIV-1 infection Phase II
DNA topical patch vaccine McLean, VA (703) 879-6803
DTP-HepB-Polio-Hib Merck diphtheria, tetanus, pertussis, Phase III
hexavalent vaccine Whitehouse Station, NJ hepatitis B, poliomyelitis, (800) 672-6372
sanofi pasteur Haemophilus influenzae type b (800) 822-2463
Swiftwater, PA (infants)
DV-601 Dynavax treatment of hepatitis B Phase I
(therapeutic vaccine) Berkeley, CA (510) 848-5100
Ebola vaccine Crucell prevention of Ebola virus infections Phase I
Leiden, Netherlands www.crucell.com
Vaccine Research Center (NIAID)
Bethesda, MD
Ebola virus vaccine GenPhar Ebola virus infections in clinical trials
Mt. Pleasant, SC (843) 884-0120
EP1043 VaxOnco prevention of HIV-1 infections Phase I
(recombinant protein vaccine) Seoul, South Korea www.vaxonco.com
National Institute of Allergy and
Infectious Diseases
Bethesda, MD
EP1090 VaxOnco prevention and treatment of HIV-1 Phase I/II
(DNA vaccine) Seoul, South Korea infections www.vaxonco.com
National Institute of Allergy and
Infectious Diseases
Bethesda, MD
Medicines in Development Vaccines 2012 13

14. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
EP1300 VaxOnco prevention of malaria Phase I
(DNA vaccine) Seoul, South Korea www.vaxonco.com
National Institutes of Health
Bethesda, MD
ETEC vaccine Vaccine Technologies prevention of cholera, Escherichia Phase I
Boston, MA coli infections (617) 358-5011
FluBlok® Protein Sciences prevention of influenza virus application submitted
influenza virus vaccine Meridian, CT infections (adults and children) (800) 488-7099
(Fast Track)
FluLaval™ GlaxoSmithKline prevention of influenza virus Phase III completed
influenza virus vaccine Rsch. Triangle Park, NC infections (888) 825-5249
(pediatric)
Fluvirin® Novartis Vaccines Diagnostics prevention of influenza A virus H1N1 Phase II/III completed
influenza A virus H1N1 vaccine Cambridge, MA subtype (pediatric) (617) 871-7000
Fluzone® QIV IM sanofi pasteur influenza virus infections Phase III
quadrivalent inactivated influ- Swiftwater, PA (800) 822-2463
enza vaccine
GelVac™ Nanotherapeutics influenza virus infections Phase I
H5N1 influenza virus vaccine Alachua, FL (386) 462-9663
intranasal
GI-5005 GlobeImmune hepatitis C (combination therapy) Phase II
(therapeutic vaccine) Louisville, CO (303) 625-2700
GSK1437173A GlaxoSmithKline prevention of varicella zoster virus Phase III
(varicella zoster vaccine) Rsch. Triangle Park, NC infections (888) 825-5249
GSK1492903A GlaxoSmithKline prevention of cytomegalovirus Phase I
(recombinant glycoprotein Rsch. Triangle Park, NC infections (888) 825-5249
vaccine)
GSK2189242A GlaxoSmithKline prevention of pneumococcal Phase II
(Streptococcus pneumoniae Rsch. Triangle Park, NC infections (888) 825-5249
recombinant conjugated
vaccine)
GSK2254232A GlaxoSmithKline prevention of Haemophilus Phase I completed
(Haemophilus influenzae, Rsch. Triangle Park, NC infections, prevention of (888) 825-5249
pneumococcal recombinant pneumococcal infections
vaccine)
14 Medicines in Development Vaccines 2012

15. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
GSK2254233A GlaxoSmithKline prevention of Haemophilus Phase I completed
(Haemophilus influenzae, Rsch. Triangle Park, NC infections, prevention of (888) 825-5249
pneumococcal recombinant pneumococcal infections
vaccine)
GSK2282512A GlaxoSmithKline prevention of influenza virus application submitted
(influenza virus vaccine) Rsch. Triangle Park, NC infections (adults, adolescents and (888) 825-5249
children)
GSK2321138A GlaxoSmithKline prevention of influenza virus application submitted
(influenza virus vaccine) Rsch. Triangle Park, NC infections (adults, adolescents and (888) 825-5249
children)
GSK2340273A GlaxoSmithKline prevention of influenza A virus Phase II
(influenza A virus Rsch. Triangle Park, NC H1N1 subtype (children and infants) (888) 825-5249
H1N1 vaccine)
GSK2340274A GlaxoSmithKline prevention of influenza A virus H1N1 Phase II
(influenza A virus vaccine) Rsch. Triangle Park, NC subtype (children and infants) (888) 825-5249
-------------------------------------------------- -------------------------------------------
influenza A virus H5N1 subtype Phase I
(888) 825-5249
GSK2392102A GlaxoSmithKline staphylococcal infections Phase I
(Staphylococcus aureus Rsch. Triangle Park, NC (888) 825-5249
vaccine)
GSK2830930A GlaxoSmithKline pneumococcal infections Phase I
(pneumococcal vaccine) Rsch. Triangle Park, NC (888) 825-5249
H5N1 influenza virus vaccine Novavax prevention of influenza A virus H5N1 Phase II
(recombinant) Rockville, MD subtype (240) 268-2000
H5N1 influenza virus vaccine Vaxart prevention of influenza A virus H5N1 Phase I
San Francisco, CA subtype (415) 437-0132
H5N1 pandemic influenza virus GlaxoSmithKline prevention of influenza A virus H5N1 application submitted
vaccine Rsch. Triangle Park, NC subtype (888) 825-5249
-------------------------------------------------- -------------------------------------------
prevention of influenza A virus H5N1 Phase III
subtype (children and adolescents) (888) 825-5249
HBV-002 Hawaii Biotech prevention of West Nile virus Phase I completed
(recombinant subunit vaccine) Aiea, HI infection (808) 486-5333
Helicobacter pylori vaccine Novartis Vaccines Diagnostics helicobacter infections Phase I
Cambridge, MA (617) 871-7000
Medicines in Development Vaccines 2012 15

16. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
hepatitis B DNA vaccine Pfizer hepatitis B Phase I
New York, NY (860) 732-5156
hepatitis B vaccine Emergent BioSolutions hepatitis B Phase II
Rockville, MD (301) 795-1800
hepatitis C vaccine Okairos prevention of hepatitis C Phase I/II
Rome, Italy www.okairos.il
hepatitis C vaccine Novartis Vaccines Diagnostics treatment of hepatitis C Phase I/II
(HCV/MF59) Cambridge, MA (617) 871-7000
Heplisav™ Dynavax prevention of hepatitis B Phase III
hepatitis B vaccine 1018-ISS Berkeley, CA (510) 848-5100
conjugate
herpes simplex DNA vaccine Pfizer treatment of herpes simplex virus Phase I
New York, NY infections (860) 732-5156
herpes simplex vaccine AuRx prevention and treatment of herpes Phase I/II
Elkridge, MD (410) 796-759
Hexaxim® sanofi pasteur diptheria, tetanus, pertussis, application submitted
DTP-HepB-Polio-Hib vaccine Swiftwater, PA hepatitis B, poliomyelitis, (800) 822-2463
Haemophilus influenzae type b
(infants)
HIVAX™ GeneCure Biotechnologies HIV-1 infection Phase I
replication-defective HIV-1 Norcross, GA (770) 263-7508
vaccine
HIV recombinant vaccine GlaxoSmithKline treatment of HIV infection Phase II
(gag/pol/nef) Rsch. Triangle Park, NC (888) 825-5249
HIV recombinant vaccine GlaxoSmithKline prevention of HIV-1 infection Phase I completed
(gp120/NefTat/AS02A) Rsch. Triangle Park, NC (888) 825-5249
HIV vaccine GeoVax Labs prevention of HIV infection Phase II
Smyrna, GA (678) 384-7220
HIV vaccine GeoVax Labs treatment of HIV infection Phase I/II
Smyrna, GA (678) 384-7220
HIV vaccine Novartis Vaccines Diagnostics HIV infection Phase I
Cambridge, MA (617) 871-7000
16 Medicines in Development Vaccines 2012

17. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
HIV vaccine Opal Therapeutics HIV infection Phase I
Palo Alto, CA (617) 726-2000
Massachusetts General Hospital
Boston, MA
HIV vaccine Profectus Biosciences prevention of HIV infection Phase I
(MAG pDNA) Baltimore, MD (866) 938-8559
HIV vaccine Profectus Biosciences prevention of HIV infection Phase I
(rVSV) Baltimore, MD (866) 938-8559
Imvamune® BM ImmunoTherapeutics smallpox Phase II
smallpox vaccine (Bavarian Nordic) (650) 681-4660
Mountain View, CA
influenza A virus H1N1 vaccine CEL-SCI prevention and treatment of influenza Phase I
Vienna, VA A virus H1N1 subtype (703) 506-9460
influenza A virus H1N1 vaccine iBio prevention of influenza A virus H1N1 Phase I
Newark, DE subtype www.ibioinc.com
Fraunhofer USA Center for
Molecular Biotechnology
Newark, DE
influenza A virus H5N1 GlaxoSmithKline prevention of influenza A virus H5N1 Phase I
cell culture-based vaccine Rsch. Triangle Park, NC subtype (pandemic use) (888) 825-5249
influenza A virus H5N1 vaccine Baxter Healthcare prevention of influenza A virus H5N1 Phase I
Deerfield, IL subtype (800) 422-9837
influenza A virus vaccine H1N1 Medicago USA prevention of influenza A virus H1N1 Phase I
Durham, NC subtype (919) 313-9670
influenza A virus vaccine H5N1 iBio prevention of influenza A virus H5N1 Phase I
Newark, DE subtype www.ibioinc.com
influenza A virus vaccine H9N2 Baxter Healthcare prevention of influenza A virus H9N2 Phase I/II
Deerfield, IL subtype (800) 422-9837
influenza virus DNA vaccine Vical prevention of influenza A virus H1N1 Phase I completed
San Diego, CA subtype (858) 646-1100
influenza virus vaccine Dynavax prevention of influenza virus Phase I
Berkeley, CA infections (510) 848-5100
influenza virus vaccine Novartis Vaccines Diagnostics influenza virus infections Phase III
(Fluad) Cambridge, MA (children and elderly) (617) 871-7000
Medicines in Development Vaccines 2012 17

18. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
influenza virus vaccine Vaxin influenza virus infections Phase I
intranasal Birmingham, AL (205) 413-8238
Influvac® TC Abbott Laboratories prevention of influenza virus Phase I
cell culture-derived influenza Abbott Park, IL infections (847) 937-6100
vaccine
INO-3510 Inovio Pharmaceuticals influenza A virus H1N1 subtype, Phase I
(DNA vaccine) Blue Bell, PA influenza A virus H5N1 subtype (877) 466-6846
Ixiaro® Intercell prevention of Japanese encephalitis Phase III
Japanese encephalitis vaccine Vienna, Austria (pediatric) (617) 871-7000
Novartis Vaccines Diagnostics
Cambridge, MA
Ii-Key hybrid peptide vaccine Antigen Express influenza A virus H1N1 subtype Phase I
Worcester, MA (508) 852-8783
LIQ-001 Liquidia Technologies influenza virus infections Phase I
Rsch. Triangle Park, NC (919) 328-4400
Lyme disease vaccine Bayer HealthCare Pharmaceuticals prevention of Lyme disease Phase I/II
Wayne, NJ (888) 842-2937
malaria DNA vaccine U.S. Naval Medical Research Center malaria Phase I/II
Silver Spring, MD (858) 646-1100
Vical
San Diego, CA
malaria vaccine GenVec malaria Phase I/II
Gaithersburg, MD (877) 943-6832
U.S. Naval Medical Research Center
Silver Spring, MD
malaria vaccine Sanaria malaria Phase I/II
Rockville, MD (301) 770-3222
malaria vaccine Crucell malaria Phase I
(recombinant) Leiden, Netherlands www.crucell.com
malaria vaccine Crucell prevention of malaria Phase I/II
(recombinant combination Leiden, Netherlands www.crucell.com
vaccine) GlaxoSmithKline (888) 825-5249
Rsch. Triangle Park, NC
Marburg virus DNA vaccine GenPhar Marburg virus disease in clinical trials
Mt. Pleasant, SC (843) 884-0120
MEDI-534 MedImmune prevention of parainfluenza and Phase I
(RSV/PIV-3 vaccine) Gaithersburg, MD respiratory syncytial virus infections (301) 398-0000
18 Medicines in Development Vaccines 2012

19. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
MEDI-550 MedImmune prevention of pandemic influenza Phase I
(pandemic influenza virus Gaithersburg, MD (H5N1 subtype) (301) 398-0000
vaccine)
MEDI-559 MedImmune prevention of respiratory syncytial Phase I
(RSV vaccine) Gaithersburg, MD virus infections (pediatric) (301) 398-0000
MenABCWY Novartis Vaccine Diagnostics prevention of meningococcal groups Phase II
(multivalent conjugate vaccine) Cambridge, MA A, B, C, Y and W-135 infections (617) 871-7000
(adolescents)
MenHibrix® GlaxoSmithKline prevention of Neisseria meningitidis application submitted
Hib-MenCY-TT conjugated Rsch. Triangle Park, NC groups C and Y infections and (888) 825-5249
vaccine Haemophilus influenzae type B
Meninge ACYW sanofi pasteur meningococcal infections Phase II
(second-generation Swiftwater, PA (800) 822-2463
meningococcal conjugate infant
vaccine)
meningococcal vaccine group B Novartis Vaccines Diagnostics meningococcal group B infections Phase II
quadrivalent recombinant Cambridge, MA (617) 871-7000
vaccine (4CMenB)
Menveo® Infants Novartis Vaccines Diagnostics prevention of meningococcal A, C, Y application submitted
meningococcal vaccine groups Cambridge, MA and W-135 infections (infants) (617) 871-7000
ACYW-135 conjugate vaccine
MMR vaccine GlaxoSmithKline prevention of measles, mumps and Phase II
(live attenuated trivalent Rsch. Triangle Park, NC rubella (888) 825-5249
vaccine)
Mosquirix™ GlaxoSmithKline malaria Phase III
malaria recombinant vaccine Rsch. Triangle Park, NC (888) 825-5249
MVA-BN® HIV BN ImmunoTherapeutics prevention and treatment of HIV-1 Phase I/II completed
HIV multiantigen vaccine (Bavarian Nordic) infection (650) 681-4660
Mountain View, CA
MVA-BN® Polytope BN ImmunoTherapeutics prevention of HIV infection Phase I
HIV vaccine (Bavarin Nordic) (650) 681-4660
Mountain View, CA
NB-1008 NanoBio prevention of influenza virus Phase I
(intranasal vaccine) Ann Arbor, MI infections (734) 302-4000
Medicines in Development Vaccines 2012 19

20. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
NDV-3 NovaDigm Therapeutics prevention of candidiasis, prevention Phase I
(recombinant protein vaccine) Grand Forks, ND of staphylococcal (MRSA) infections (701) 757-5161
Nimenrix™ GlaxoSmithKline prevention of meningococcal groups Phase III
MenACWY-TT conjugated Rsch. Triangle Park, NC A, C, Y and W-135 infections (888) 825-5249
vaccine (children)
-------------------------------------------------- -------------------------------------------
prevention of meningococcal groups Phase II
A, C, Y and W-135 infections (888) 825-5249
(adults, adolescents, infants)
NmVac JN-International Medical prevention of meningococcal groups Phase I
(meningococcal vaccine groups Omaha, NE A, C, Y, and W-135 infections (402) 884-3477
ACWY conjugate vaccine)
norovirus bivalent vaccine LigoCyte Pharmaceuticals norovirus infections Phase I
Bozeman, MT (406) 585-2733
norovirus monovalent vaccine LigoCyte Pharmaceuticals norovirus infections Phase I/II
Bozeman, MT (406) 585-2733
Optaflu® Novartis Vaccines Diagnostics prevention of influenza virus application submitted
influenza virus vaccine Cambridge, MA infections (617) 871-7000
PanBlok™ Protein Sciences prevention of influenza A virus H5N1 Phase I/II
influenza A virus H5N1 vaccine Meriden, CT subtype (pandemic) (800) 488-7099
parvovirus B19 vaccine Meridian Biosciences parvovirus infections Phase I/II
Cincinnati, OH (513) 271-3700
PENNVAX™-B Inovio Pharmaceuticals prevention and treatment of HIV Phase I
DNA vaccine (clade B) Blue Bell, PA infection (267) 440-4200
PENNVAX™-G Inovio Pharmaceuticals prevention of HIV infection Phase I
DNA vaccine (clade A, C, D) Blue Bell, PA (267) 440-4200
PER.C-flu vaccine Crucell prevention of influenza virus Phase II
Leiden, Netherlands infections www.crucell.com
PF-05212366 Pfizer adolescent meningitis Phase II
(MnB rLP2086) New York, NY (860) 732-5156
-------------------------------------------------- -------------------------------------------
infant meningitis Phase I
(860) 732-5156
PF-06290510 Pfizer staphylococcal infections Phase II
(4-antigen Staphylococcus New York, NY (860) 732-5156
aureus vaccine)
plague vaccine injectable DynPort Vaccine Yersinia infections Phase II
Frederick, MD (301) 607-5000
20 Medicines in Development Vaccines 2012

21. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Preflucel™ Baxter Healthcare prevention of influenza virus Phase III
seasonal influenza virus vaccine Deerfield, IL infections (800) 422-9837
Pseudomonas aeruginosa sanofi pasteur prevention of ventilator-associated Phase I
antibody fragment product Swiftwater, PA pneumonia (800) 822-2463
PXVX-0103 PaxVax prevention of influenza A virus Phase I
(H5N1 influenza vaccine) Menlo Park, CA H5N1 infections www.paxvax.com
Q-LAIV Flu MedImmune seasonal influenza application submitted
(MEDI-3250 vaccine) Gaithersburg, MD (301) 398-0000
Quadracel® sanofi pasteur diphtheria, tetanus, pertussis and Phase III
diphtheria and tetanus toxoids Swiftwater, PA polio vaccine (in children 4-6 years (800) 822-2463
and acellular pertussis vaccine of age)
adsorbed combined with
inactivated poliomyelitis vaccine
rabies VRVg sanofi pasteur prevention of rabies infection Phase II
(purified vero rabies vaccine) Swiftwater, PA (800) 822-2463
respiratory syncytial virus VLP Novavax prevention of respiratory syncytial Phase I
vaccine Rockville, MD virus (RSV) infections (240) 268-2000
RiVax™ Soligenix prevention of ricin poisoning Phase I
ricin vaccine Princeton, NJ (609) 538-8200
(Orphan Drug)
rotavirus vaccine sanofi pasteur prevention of rotavirus infections Phase I
(live attenuated tetravalent oral Swiftwater, PA (800) 822-2463
vaccine)
rotavirus vaccine I321 Bharat Biotech prevention of rotavirus infections Phase I
Hyderabad, India www.bharatbiotech.com
rPA-102 Emergent BioSolutions anthrax Phase II
(recombinant protective antigen Rockville, MD (Fast Track) (301) 795-1800
anthrax vaccine)
Shigella vaccine Emergent BioSolutions Shigella infections Phase I
Rockville, MD (301) 795-1800
SparVax™ PharmAthene anthrax Phase II completed
recombinant protective antigen Annapolis, MD (pre- and post-exposure prevention) (410) 269-2600
(rPA) anthrax vaccine
Staphylococcus aureus vaccine Novartis Vaccines Diagnostics staphylococcal infections Phase I
Cambridge, MA (617) 871-7000
Medicines in Development Vaccines 2012 21

22. Medicines in Development for Vaccines
Infectious Diseases
Product Name Sponsor Indication Development Status
Staphylococcus aureus vaccine GlaxoSmithKline Gram-positive infections, Phase I/II
conjugate pentavalent Rsch. Triangle Park, NC staphylococcal infections (888) 825-5249
streptococcal B vaccine Emergent BioSolutions streptococcal infections Phase I
Rockville, MD (301) 795-1800
streptococcal B vaccine Novartis Vaccines Diagnostics prevention of streptococcal infections Phase II
conjugate Cambridge, MA (617) 871-7000
Streptococcus pneumoniae sanofi pasteur meningitis and penumonia Phase I
vaccine Swiftwater, PA (800) 822-2463
TCN-032 Theraclone Sciences influenza A virus infections Phase I
(mAb vaccine) Seattle, WA (206) 805-1600
TG-4040 Transgene hepatitis C Phase II
(vector-based therapeutic Rockville, MD (301) 816-5421
vaccine)
TransVax™ Astellas Pharma US prevention of cytomegalovirus Phase II
cytomegalovirus DNA vaccine Deerfield, IL infections (800) 695-4321
(Orphan Drug) Vical (858) 646-1100
San Diego, CA
tuberculosis recombinant sanofi pasteur prevention of tuberculosis Phase I
subunit vaccine Swiftwater, PA (800) 822-2463
tuberculosis vaccine Aerus Global TB Vaccine Foundation prevention of tuberculosis Phase I
Rockville, MD www.crucell.com
Crucell
Leiden, Netherlands
tularemia vaccine DynPort Vaccine prevention of tularemia Phase I
Frederick, MD (301) 607-5000
TUTI-16 Thymon HIV-1 infection Phase I/II
(synthetic lipopeptide vaccine) Short Hills, NJ (973) 467-9558
Typhella™ Emergent BioSolutions prevention of typhoid Phase II completed
typhoid vaccine oral Rockville, MD (301) 795-1800
typhoid vaccine Novartis Vaccines Institute for prevention of typhoid Phase II
Global Health (888) 669-6682
Siena, Italy
V114 Merck prevention of pneumococcal Phase II
(pneumococcal 15 valent Whitehouse Station, NJ infections (infants) (800) 672-6372
conjugate vaccine)
22 Medicines in Development Vaccines 2012